The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student ...
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures," said ...
Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
Gvoke VialDx has the potential to modernize the handling and administration of glucagon for diagnostic procedures,” said Kevin McCulloch, President and COO of Xeris. “American Regent is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback